NCT03476655 - Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2018

Primary Completion Date

May 14, 2019

Study Completion Date

May 31, 2019

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell

Interventions

DRUG

Ibrutinib

No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.

Trial Locations (8)

110029

All India Institute of Medical Sciences, New Delhi

122002

Fortis Memorial Research Institute, Gūrgaon

302017

Bhagwan Mahaveer Hospital & Research Centre, Jaipur

382428

Apollo Hospitals International Limited, Ahmedabad

411002

Yashoda Hematology Clinic, Pune

500034

Basavatarakam Indo-American Hospital, Hyderabad

560013

Healthcare Global (HCG) Hospital, Bangalore

700156

Tata Medical Center, Kolkata